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RESULTS: The reported SG, TTO, EuroQol, and RS utili-
ties were on average 0.89, 0.88, 0.70, and 0.69. The RS util-
ity as it would be without heartburn was 0.84. The predic-
tion models showed that the EuroQol and RS utilities were
negatively related to heartburn severity and frequency. A
logarithmic transformation of heartburn frequency de-
scribed the functional relationship between frequency and
utilities best. The EuroQol, SG, and TTO utilities increased
with age. Women reported lower EuroQol and RS utilities
and higher SG utilities than men did. German patients re-
ported lower RS utilities than Swedish patients did. The pre-
dicted EuroQol (and RS) utilities by severity of heartburn
were 0.75 (0.72), 0.67 (0.67), and 0.50 (0.61).
CONCLUSION: Our results indicate that patients assign
substantial disability to heartburn. The results also indicate
that utilities may be predicted from heartburn severity and
frequency and other patient characteristics. The assessed
utilities and the prediction models may provide a basis for
future cost-utility analyses of GERD interventions.
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OBJECTIVE: Posterior Capsular Opacification (PCO) is
the most frequent long-term complication of cataract sur-
gery with some different incidence rates across the intra-
ocular lenses (IOL). PCO is treated with Neodimium:Yag
(Nd:Yag) laser. The aim of this model was to evaluate the
clinical long-term consequences of Nd:Yag laser capsul-
otomy complications over the patient’s life.
METHODS: A 19-state Markov model was constructed
including the 14 states describing the Nd:Yag laser com-
plications reported in the literature: PCO; Nd:Yag laser;
post Nd:Yag laser; blindness and death. Probability to
die was modeled from national mortality tables as a poly-
nomial function of gender and age. Probability to become
blind was modeled as a function of age from literature
data. Incidence of Nd:Yag complications came from the
literature. The shape of the long term Nd:Yag laser use
incidence-survival curve was modeled from a cohort of
3335 patients with a maximum follow-up of 10 years.
Parameters of the modified Rayleigh function were esti-
mated according to least square mean method. Full sensi-
tivity analyses were conducted.
RESULTS: Switching a whole 70-year old population (1
male:1 female) from a 20% Nd:Yag laser incidence rate
of IOL at 3 years to 5% would avoid one chronic intra-
ocular pressure increase every 54 to 66 surgeries, one visual-
acuity decrease every 111 to 137 surgeries, one glaucoma
every 238 to 292 surgeries, one cystoid macular oedema
every 265 to 326 surgeries, one retinal detachment every
265 to 326 surgeries over the patient’s life. A three year
clinical study would only capture one third to one half of
the long term Nd:Yag adverse events.
CONCLUSION: Based on the results of this Markov
model, long term use of Nd:Yag laser being estimated on
a 10-year follow-up cohort, PCO rate is reduced, and
therefore the use of Nd:Yag laser might contribute to pre-
serving patient’s visual acuity over their full life.
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OBJECTIVE: The aim of this study was to compare the
costs and clinical consequences of olopatadine, a NCE
with a dual mechanism of action (anti-histamine and
mast cell stabilizer) with topical levocabastine for the
treatment of seasonal allergic conjunctivitis (SAC) in Bel-
gium, France, Germany, Netherlands, Norway, Portugal
and Sweden.
METHODS: A randomized, controlled, double-blind,
multi-country clinical trial compared the efficacy and
safety of olopatidine 0.1% bid and levocabastine 0.05%
qid. An economic comparison of first-line treatment fail-
ures with olopatadine versus levocabastine was modeled
using clinical trial results and a standard cost approach.
A societal perspective was adopted. Indirect resource uti-
lization was estimated from the clinical trial. Cost of fail-
ure was established from Pinto.
RESULTS: 210 patients (101 olopatadine, 109 levo-
cabastine) with SAC were treated over 42 days. At day
42, olopatadine-treated patients had a lower redness
score (P  0.05) while the difference in itching scores
was close to statistical significance (P  0.062). The first-
line treatment-failure rate was 15.8% less (P  .01) in ol-
opatadine-treated patients. Olopatadine patients had a
1.47 greater chance (P  .0001) of having a day without
symptoms. Olopatadine was well tolerated. Time lost due
to SAC was lower than 1 hour on average. Cost of failure
varied across countries from €48 to €72 . Savings per
episode due to first-line failures avoided with olopatadine
were €8.84 in Belgium, €10.97 in France, €10.94 in
Germany, €7.74 in NL, €7.61 in Norway, €10.65 in
Portugal and €11.33 in Sweden. Sensitivity analyses con-
firmed the robustness of our findings.
CONCLUSION: Based on results of a randomized clini-
cal trial, and resources and costs associated with failure
estimated from the literature, our model found that olo-
patadine is a cost-saving alternative to levocabastine and
provides more clinical benefits to patients. Results were
consistent over all study countries.
